Skip to main content
Back to Our Blog

Kentucky Board of Pharmacy Rejects the HHS Peptide Enforcement Policy for Six Compounded Peptides

Camino Strategy Group

What happened

On November 18, 2026, the Kentucky Board of Pharmacy voted to enforce its compounding regulation, 201 KAR 2:076, as written, and declined to grant waivers for six peptides that the federal government had just signaled it would not pursue. The following day, the Board sent a compliance alert to Kentucky pharmacies and to nonresident pharmacies licensed to ship into the state, stating that they may not compound, dispense, or ship preparations containing these peptides to patients or practitioners in Kentucky.

The six peptides are:

  • BPC-157
  • TB-500 (thymosin beta-4 fragment)
  • Epitalon
  • Semax
  • KPV
  • MOTS-c

The Board's position is that none of the six has ever met Kentucky's requirements for compounding, which means compounding them for Kentucky patients was never authorized in the first place. According to reporting on the alert, there is no grace period, and pharmacies that do not follow the rule put their permit at risk or face fines.

The federal policy Kentucky is responding to

To understand why this matters, it helps to look at how quickly the federal picture moved this year. In April 2026, FDA removed BPC-157 from Category 2 of the 503A bulks evaluation, which lifted its "significant safety risk" flag but did not add it to the list of substances that can be used in compounding. In July 2026, FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend allowing prescription-only compounding of six of them, even though FDA's own scientific staff raised concerns about gaps in the data.

Then on October 30, 2026, HHS announced an interim enforcement discretion policy for those six peptides. Under that policy, the federal government does not intend to take action against 503A compounding pharmacies using these peptides, as long as certain conditions are met, including identity and route of administration specifications for each peptide and a valid certificate of analysis from the bulk ingredient manufacturer.

What the policy does not do is just as important as what it does. It does not approve these peptides, it does not add them to FDA's 503A bulks list, and it does not override state law. Enforcement discretion is a statement about where the federal government plans to spend its enforcement resources, not a change in what the law actually permits. A lot of the market read it as a green light anyway, and Kentucky is the first state board to say out loud that it is not one.

Why Kentucky reached a different answer

Kentucky's compounding rule sets its own eligibility test for the ingredients a pharmacy can use to compound a drug for human use. In general terms, the substance has to have an applicable USP or NF monograph, be a component of an FDA-approved human drug, or appear on FDA's 503A bulks list. A federal decision not to enforce does not place any of these six peptides into any of those categories, so from the Board's point of view, nothing about the state law analysis changed on October 30.

This is consistent with how Kentucky has approached compounding more broadly. The Board has relied on the same regulation in its guidance on compounded semaglutide and tirzepatide, and it has generally treated federal flexibility as something that sits on top of state requirements rather than replacing them.

Other states are weighing in

Kentucky is not alone in questioning how much weight the federal policy carries. On November 10, the Alabama Board of Medical Examiners published an FAQ stating that HHS enforcement discretion neither overrides state law nor establishes compliance with Section 503A. Alabama has not announced a prohibition, but its guidance raises the same question Kentucky answered directly. Separately, the Alabama Board of Pharmacy issued a GLP-1 compounding advisory cautioning against routine ingredient additions, standardized justifications, and preselected responses on prescribing platforms.

The Alliance for Pharmacy Compounding summed up the situation by noting that federal policy does not guarantee uniform treatment across states, and it is reasonable to expect more boards to issue their own positions in the coming weeks.

Why this matters for multi-state telehealth

The part of this that stands out to me is the nonresident pharmacy piece. Kentucky's alert does not only apply to pharmacies located in Kentucky. It applies to any pharmacy licensed to ship into the state, which means the rule follows the patient's location rather than where the pharmacy or the telehealth company sits. For companies that sell, distribute, or fulfill peptides nationally through mail-order pharmacies, the federal policy now comes with at least one state carve-out, and possibly more to follow.

The market noticed. Bank of America cut its price target on Hims & Hers the day after the vote, citing the Kentucky decision.

This is a familiar pattern. During the semaglutide and tirzepatide shortages, a lot of companies learned that a federal pathway opening or closing was only half of the story, and that state pharmacy and medical boards hold the licenses and set the rules that actually govern what ships to their residents. Peptides are following the same path. I am personally excited to see more structure around peptides, because it is what will eventually let patients get the right product, prescribed and taken appropriately, but that structure is going to be built state by state, not all at once.

Bottom line

Federal allowance does not equal state approval. The HHS enforcement discretion policy changed the federal enforcement posture for six peptides, but it did not change Kentucky law, and the Kentucky Board of Pharmacy has made clear that compounding these peptides for Kentucky patients remains off the table for resident and nonresident pharmacies alike.

Sources

This article is for general informational purposes only and is not legal advice. Please consult qualified legal counsel about your specific situation.

Building foundations that scale | caminostrategygroup.com

Have a compliance question?

Reading about it is step one. Send it our way.

If this article hits close to home — your structure, your states, your launch — tell us what you’re building. We read every submission and reply by email within one business day.

No sales calls. Educational content only — not legal advice.